156 related articles for article (PubMed ID: 24939622)
41. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
42. Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities.
Navrátil M; Tykvart J; Schimer J; Pachl P; Navrátil V; Rokob TA; Hlouchová K; Rulíšek L; Konvalinka J
FEBS J; 2016 Jul; 283(13):2528-45. PubMed ID: 27208881
[TBL] [Abstract][Full Text] [Related]
43. A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging.
Vorlová B; Sedlák F; Kašpárek P; Šrámková K; Malý M; Zámečník J; Šácha P; Konvalinka J
Prostate; 2019 Feb; 79(2):126-139. PubMed ID: 30256431
[TBL] [Abstract][Full Text] [Related]
44. Valproate promotes survival of retinal ganglion cells in a rat model of optic nerve crush.
Zhang ZZ; Gong YY; Shi YH; Zhang W; Qin XH; Wu XW
Neuroscience; 2012 Nov; 224():282-93. PubMed ID: 22867974
[TBL] [Abstract][Full Text] [Related]
45. Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions.
Fukuchi M; Nii T; Ishimaru N; Minamino A; Hara D; Takasaki I; Tabuchi A; Tsuda M
Neurosci Res; 2009 Sep; 65(1):35-43. PubMed ID: 19463867
[TBL] [Abstract][Full Text] [Related]
46. Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells.
Papi A; Ferreri AM; Rocchi P; Guerra F; Orlandi M
Anticancer Res; 2010 Feb; 30(2):535-40. PubMed ID: 20332466
[TBL] [Abstract][Full Text] [Related]
47. Valproate administration to mice increases histone acetylation and 5-lipoxygenase content in the hippocampus.
Yildirim E; Zhang Z; Uz T; Chen CQ; Manev R; Manev H
Neurosci Lett; 2003 Jul; 345(2):141-3. PubMed ID: 12821190
[TBL] [Abstract][Full Text] [Related]
48. Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain.
Kim MJ; Chae SS; Koh YH; Lee SK; Jo SA
FASEB J; 2010 Nov; 24(11):4491-502. PubMed ID: 20624932
[TBL] [Abstract][Full Text] [Related]
49. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
[TBL] [Abstract][Full Text] [Related]
50. Epigenetic induction of melatonin MT
Bahna SG; Niles LP
Eur Neuropsychopharmacol; 2017 Aug; 27(8):828-832. PubMed ID: 28648552
[TBL] [Abstract][Full Text] [Related]
51. Detection and quantitation of glutamate carboxypeptidase II in human blood.
Knedlík T; Navrátil V; Vik V; Pacík D; Šácha P; Konvalinka J
Prostate; 2014 May; 74(7):768-80. PubMed ID: 24647901
[TBL] [Abstract][Full Text] [Related]
52. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells.
Castro LM; Gallant M; Niles LP
J Neurochem; 2005 Dec; 95(5):1227-36. PubMed ID: 16313512
[TBL] [Abstract][Full Text] [Related]
53. Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain.
Zhang Z; Bassam B; Thomas AG; Williams M; Liu J; Nance E; Rojas C; Slusher BS; Kannan S
Neurobiol Dis; 2016 Oct; 94():116-28. PubMed ID: 27326668
[TBL] [Abstract][Full Text] [Related]
54. The histone deacetylase (HDAC) inhibitor valproic acid reduces ethanol consumption and ethanol-conditioned place preference in rats.
Al Ameri M; Al Mansouri S; Al Maamari A; Bahi A
Brain Res; 2014 Oct; 1583():122-31. PubMed ID: 25108044
[TBL] [Abstract][Full Text] [Related]
55. Valproic acid phase shifts the rhythmic expression of Period2::Luciferase.
Johansson AS; Brask J; Owe-Larsson B; Hetta J; Lundkvist GB
J Biol Rhythms; 2011 Dec; 26(6):541-51. PubMed ID: 22215612
[TBL] [Abstract][Full Text] [Related]
56. Epigenetic landscape of amphetamine and methamphetamine addiction in rodents.
Godino A; Jayanthi S; Cadet JL
Epigenetics; 2015; 10(7):574-80. PubMed ID: 26023847
[TBL] [Abstract][Full Text] [Related]
57. Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles.
Neburkova J; Sedlak F; Zackova Suchanova J; Kostka L; Sacha P; Subr V; Etrych T; Simon P; Barinkova J; Krystufek R; Spanielova H; Forstova J; Konvalinka J; Cigler P
Mol Pharm; 2018 Aug; 15(8):2932-2945. PubMed ID: 29389139
[TBL] [Abstract][Full Text] [Related]
58. Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors.
Urazaev AK; Grossfeld RM; Lieberman EM
J Neurochem; 2005 May; 93(3):605-10. PubMed ID: 15836619
[TBL] [Abstract][Full Text] [Related]
59. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
60. Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II.
Navrátil M; Ptáček J; Šácha P; Starková J; Lubkowski J; Bařinka C; Konvalinka J
FEBS J; 2014 Jul; 281(14):3228-42. PubMed ID: 24863754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
